Axillary Dissection May Be Unnecessary for Many Breast Cancer Patients

Publication
Article
OncologyONCOLOGY Vol 13 No 10
Volume 13
Issue 10

A new decision-making model developed by Dr.Giovanni Parmigiani and colleagues at Duke University has shown that the routine use of axillary lymph node dissection may not be necessary for many breast cancer patients. Recently, the use of

A new decision-making model developed by Dr.Giovanni Parmigiani and colleagues at Duke University has shown that the routine use of axillary lymph node dissection may not be necessary for many breast cancer patients. Recently, the use of axillary dissection has been questioned because lymph node status may not alter adjuvant therapy and because the survival benefit resulting from a change in adjuvant therapy would be small.

Only a Select Group of Patients May Benefit

The decision-making model was developed to quantify the survival benefits of axillary lymph node dissection in breast cancer patients receiving breast-conserving therapy. According to the model, axillary dissection only provides a small survival benefit in this population and is of greatest benefit to estrogen receptor positive women with small primary tumors who might not be eligible for adjuvant chemotherapy because their lymph nodes are negative. The model suggests that routine use of axillary lymph node dissection should be reassessed, and may be necessary only in select groups of patients.

Axillary lymph node dissection can cause numbness, swelling, and a decreased range of motion of the shoulder. Because of these side effects, sentinel node biopsy is currently being examined as a less invasive alternative.

Future studies will explore the use of the decision model as a counseling tool to help physicians and patients make better informed decisions regarding axillary lymph node dissection.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content